{"id":"W2739450639","doi":"10.1182/blood.v128.22.1831.1831","title":"Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Quality of life (healthcare); Cohort; Brentuximab vedotin; Oncology; Visual analogue scale; Cancer; Lymphoma; Surgery; Hodgkin lymphoma; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003517273,0.000670408,0.001204023,0.0004303044,0.0003330704,0.0008185944,0.0005828883,0.0007075995,0.001743288],"category_scores_gemma":[0.003431071,0.000250786,0.00346814,0.0004412235,0.0002572823,0.0004948765,0.0004810439,0.0007286057,0.000140968],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000533949,"about_ca_system_score_gemma":0.0005053284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007086587,"about_ca_topic_score_gemma":0.001671599,"domain_scores_codex":[0.9986421,0.0006363732,0.0001287281,0.0003371661,0.0001440628,0.0001115268],"domain_scores_gemma":[0.9978147,0.0007728442,0.0005931273,0.0003324856,0.0001663085,0.0003205891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4269757,0.001966829,0.5046852,0.0009468294,0.03336724,0.000293606,0.0002524812,0.001132509,0.007141665,0.0001815097,0.001884598,0.02117178],"study_design_scores_gemma":[0.0275259,0.03140129,0.9170256,0.00009224513,0.01624287,0.0004206414,0.0002141667,0.00329284,0.001485265,0.0002482437,0.00197781,0.00007319655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997313,0.001450227,0.0001189701,0.00005853815,0.00003197769,0.0001230781,0.0007422805,0.000006218924,0.0001557526],"genre_scores_gemma":[0.9978976,0.0001209201,0.0001879105,0.00009664014,0.00004275921,0.0001585546,0.001357258,0.00000306925,0.0001352747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003517273,"threshold_uncertainty_score":0.0186013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01904726363066952,"score_gpt":0.298920479910761,"score_spread":0.2798732162800915,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}